摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Methyl-2-(4-methylphenyl)morpholine

中文名称
——
中文别名
——
英文名称
4-Methyl-2-(4-methylphenyl)morpholine
英文别名
——
4-Methyl-2-(4-methylphenyl)morpholine化学式
CAS
——
化学式
C12H17NO
mdl
——
分子量
191.27
InChiKey
QSOOPCZZHJECSU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    12.5
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • [EN] COMPOUNDS AS CD73 INHIBITORS<br/>[FR] COMPOSÉS UTILISÉS EN TANT QU'INHIBITEURS DE CD73
    申请人:ADORX THERAPEUTICS LTD
    公开号:WO2022090711A1
    公开(公告)日:2022-05-05
    The present invention relates to compounds of formula I shown below: wherein R1and R2are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine CD73 activity is implicated, such as, for example, cancer.
    本发明涉及以下式子的化合物:其中R1和R2在本申请中分别定义。本发明还涉及制备这些化合物的过程,包括它们的制药组合物,以及它们在治疗与腺苷CD73活性有关的疾病或病况方面的用途,例如癌症。
  • [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
    申请人:PAKINAX PTY LTD
    公开号:WO2022000031A1
    公开(公告)日:2022-01-06
    Described herein are compounds that are inhibitors of p21-activated kinases (PAKS). In particular, the compounds described herein are demonstrated to be selective PAK4 inhibitors. The compounds described herein are also demonstrated to reduce the expression of key immune checkpoint molecules, such as PD-1 and CHEK2. Also described herein are pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, more specifically, the treatment of pancreatic and lung cancers, and to related uses.
    本文描述了一些抑制p21激活激酶(PAKS)的化合物。特别地,本文描述的化合物被证明是选择性PAK4抑制剂。本文描述的化合物还被证明可以减少关键的免疫检查点分子的表达,例如PD-1和CHEK2。本文还描述了含有这些化合物的药物组合物,使用这些化合物治疗癌症的方法,更具体地说,治疗胰腺和肺癌,以及相关用途。
  • LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT
    申请人:Umemura Eijirou
    公开号:US20100184746A1
    公开(公告)日:2010-07-22
    An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R 1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R 1 represents aryl or a five- or six-membered monocyclic heterocyclic group; R 2 represents a hydrogen atom or C 1-6 alkyl; R 3 represents C 1-6 alkyl or C 3-6 cycloalkyl-C 1-4 alkyl; R 4 , R 5 , and R 6 represent a hydrogen atom; R 7 represents C 1-6 alkyl; and m is 1 to 3. The compounds are novel lincosamide derivatives that have a potent activity against resistant Streptococcus pneumoniae . Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.
    本发明的目标是提供式(I)的化合物或其药理学上可接受的盐或溶剂,其中A代表芳基,而R1代表五元或六元单环杂环基,或A代表四至六元单环杂环基,而R1代表芳基或五元或六元单环杂环基;R2代表氢原子或C1-6烷基;R3代表C1-6烷基或C3-6环烷基-C1-4烷基;R4、R5和R6代表氢原子;R7代表C1-6烷基;m为1至3。这些化合物是新型的林可霉素生物,对耐药性肺炎链球菌具有强效活性。此外,这些化合物可用作抗微生物剂,对预防或治疗细菌感染性疾病有用。
  • Lincomycin Derivatives and Antimicrobial Agents Comprising the Same as Active Ingredient
    申请人:Umemura Eijirou
    公开号:US20090156512A1
    公开(公告)日:2009-06-18
    This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R 1 represents a halide, nitro, substituted C 1-6 alkyl, optionally substituted amino, C 1-6 alkyloxycarbonyl, optionally substituted aryl, a heterocyclic group, or heterocyclic carbonyl, R 2 represents a hydrogen atom or C 1-6 alkyl, R 3 represents C 1-6 alkyl, all of R 4 , R 5 , and R 6 represent a hydrogen atom, R 7 represents C 1-6 alkyl, m is 1 or 2, and n is 1. The compounds are novel lincomycin derivatives having a potent activity against resistant pneumococci. The compounds can be used as an antimicrobial agent and are useful for preventing or treating bacterial infectious diseases.
    本发明提供了式(I)的化合物或其药理学上可接受的盐或溶剂,其中A代表芳基或单环或双环杂环基,R1代表卤素、硝基、取代的C1-6烷基、可选取代的基、C1-6烷氧羰基、可选取代的芳基、杂环基或杂环羰基,R2代表氢原子或C1-6烷基,R3代表C1-6烷基,R4、R5和R6均代表氢原子,R7代表C1-6烷基,m为1或2,n为1。这些化合物是新型的林可霉素生物,对耐药性肺炎球菌具有强大的活性。这些化合物可以用作抗微生物剂,并且对于预防或治疗细菌感染性疾病是有用的。
  • Nouveaux dérivés de 2-tolyl-morpholine utiles en thérapeutique
    申请人:LABORATOIRE L. LAFON Société anonyme dite:
    公开号:EP0138716A2
    公开(公告)日:1985-04-24
    La présente invention a trait à de nouveaux dérivés de 2-tolyl-morpholine, à savoir plus précisément a) la 2-p-tolyl-4-isopropyl-morpholine et ses sels d'addition, b) la 2-m-tolyl-4-méthyl-morpholine et ses sels d'addition, c) la 2-p-tolyl-4-méthyl-morpholine et ses sels d'addition, d) la 2-o-tolyl-4-tertiobutyl-morpholine et ses sels d'addition, e) la 2-p-tolyl-4-tertiobutyl-morpholine et ses sels d'addition, et, f) la 2-(m-trifluorométhylphényl)-2-hydroxy-4-éthyl-4- éthyl-morpholine et ses sels d'addition. Ces nouveaux dérivés sont utiles en thérapeutique, notamment en tant qu'agents actifs sur le SNC.
    本发明涉及新的 2-甲苯基吗啉衍生物,更具体地说是 a) 2-对甲苯基-4-异丙基-吗啉及其加成盐、 b) 2-甲基-4-甲苯基-吗啉及其加成盐、 c) 2-对甲苯基-4-甲基-吗啉及其加成盐、 d) 2-o-tolyl-4-tertiobutyl-morpholine 及其加成盐、 e) 2-对甲苯基-4-叔丁基吗啉及其加成盐,以及 f) 2-(间三甲基苯基)-2-羟基-4-乙基-4-乙基吗啉及其加成盐。 这些新衍生物可用于治疗,特别是作为中枢神经系统的活性剂。
查看更多